CAR T-cell therapy
New possibilities in the fight against some of the most difficult-to-treat cancers due to new cell therapies that use their own immune cells. At Bristol Myers Squibb, we focus on the development and making available of autologous Chimeric Antigen Receptor (CAR) T-cell therapy for these types of cancer. We are committed to supporting you and the patient as best as possible during the entire CAR T-cell therapy journey.1
What is CAR T?
CAR T-cell therapy is a form of immunotherapy in which the cells of the patient are used to attack the tumor. It strengthens the patient’s own T cells to recognize and bind to proteins (tumor-associated antigens) – which also occur on healthy cells – on the surface of cancer cells and kill the cells. CAR T-cell therapy is made specifically for each individual patient using his or her own T-cells. After a single treatment, the CAR T cells can continue to multiply in the patient’s body and kill tumor cells with a specific protein.2,3
How are CAR-T cells made?2-4
CAR-T cell therapy is made with individual T-cells from the patient. The therapy is therefore tailor-made for each individual.
References:
- Bristol Myers Squibb. https://www.bms.com/life-and-science/science/looking-to-the-future-of-car-t-cell-therapy.html Accessed 2024.
- Hartmann J, SchuBler-Lenz M, Bondanza A, Buchaholz CJ. EMBO Mol Med. 2017;9(9):1183-1197
- Boyiadzis MM, Dhodapkar MV, Brentjens RJ, et al., J Immnother Cancer. 2018;6(1):137
- Maus MV, Levine BL Oncologist. 2016;21(5):608-617
2009-BE-2500002 – January 2026